Topics Discussed
- Will quality and reimbursement reforms create a “year of reckoning” for mature brands in China?
- How fast is market access improving in China for innovative products?
- Has the war for talent in China reached a boiling point?
- Can local biopharma innovation compete with multinational products in China?
- How will digitization improve physician and patient engagement in China?
- Plus: The third edition of McKinsey’s China Drug Innovation Index (CDII)